Search hospitals > Iowa > Davenport

Iowa Cancer Specialists

Claim this profile
Davenport, Iowa 52807
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast cancer
Conducts research for Lung Carcinoma
33 reported clinical trials
1 medical researcher
Photo of Iowa Cancer Specialists in DavenportPhoto of Iowa Cancer Specialists in Davenport

Summary

Iowa Cancer Specialists is a medical facility located in Davenport, Iowa. This center is recognized for care of Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast cancer, Lung Carcinoma and other specialties. Iowa Cancer Specialists is involved with conducting 33 clinical trials across 38 conditions. There are 1 research doctors associated with this hospital, such as David M. Spector.

Area of expertise

1Breast Cancer
Global Leader
Iowa Cancer Specialists has run 11 trials for Breast Cancer. Some of their research focus areas include:
HER2 positive
ER positive
HER2 negative
2Lung Cancer
Global Leader
Iowa Cancer Specialists has run 11 trials for Lung Cancer. Some of their research focus areas include:
Stage III
Stage II
Stage I

Top PIs

Clinical Trials running at Iowa Cancer Specialists

Lung Cancer
Non-Small Cell Lung Cancer
ALK Gene Rearrangement
Cancer
Squamous Cell Carcinoma
Anaplastic Large Cell Lymphoma
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Iowa Cancer Specialists?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security